Introduction
Motion sickness presents a constant challenge for pharmacological management. Its prevalence is high, it causes substantial disability (Daunton, 1983; Wood, 1979) , and to date, the optimal drug regimen that will prevent the evolvement of this syndrome without causing disturbing side-effects, has not yet been found.
One of the major advances in this field in recent years was the development of a transdermal controlledrelease preparation of hyoscine, a competitive blocker of the muscarinic cholinergic receptors. This formulation was developed to utilize the potential of hyoscine as one of the most effective drugs for motion sickness, while constantly maintaining drug levels within its relatively small therapeutic window (Clissold & Heel, 1985) .
However, accumulated experience with the transcutaneous formulation shows, that along with its remarkable performance (40%-80% protection against motion sickness), it cannot fully address the problem of hyoscine side effects (Babin et al., 1984; Clissold & Heel, 1985; Homick et al., 1983) . Some of these effects, (e.g. hypo-salivation, impairment of near vision, drowsiness) are caused by very low drug levels (Shaw & Urquhart, 1980) , and thus cannot be avoided unless the efficacy of the drug regimen is abolished.
A second step, that might be useful as the approach of pharmacokinetic modulation has been exhausted, is to combine transdermal hyoscine therapy with treatment with a second drug. That drug should selectively suppress hyoscine adverse-effects, while preserving its anti-motion-sickness activity.
It is generally agreed, that the effect of hyoscine in motion sickness is due to its activity within the central nervous system (CNS) (Stott et al., 1989; Watt, 1983; Wood, 1979) . As some of the most prevalent side effects of hyoscine are due to its peripheral antimuscarinic activity, we suggest pyridostigmine, a peripherally-acting acetylcholine-esterase inhibitor as the adjunctive drug to suppress them.
Pyridostigmine is very widely used (in doses of up to 300-600 mg day-) for myasthenia gravis. As a quarternary amine its penetration through the blood-brain- (Borland, 1985; Gall, 1981; Graham et al., 1984; Glikson et al., 1991) . We therefore designed the double-blind placebo controlled study, aimed to test the value of this low dosage of pyridostigmine (30 mg three times daily) in preventing the peripheral adverse effects of transdermal hyoscine.
As impairment of salivation is the most frequent side effect reported during transdermal hyoscine therapy (experienced by over two thirds of patients) (Clissold & Heel, 1985) , it was chosen as the pharmacodynamic parameter through which drug interaction was to be characterised.
A challenge of a double dose of transdermal hyoscine patches was applied for 48 h. Salivation was repeatedly measured during that period, as well as 14 h after cessation of therapy. Measurements of blood acetylcholinesterase activity were also performed, serving as an index of pyridostigmine bioavailability.
Methods

Subjects
Forty-seven volunteers, age 18-21 years, were enrolled in the study. Inclusion criterion was normal medical status as assessed by medical history, physical examination, ECG, routine blood analysis, and normal blood acetylcholinesterase (AchE) activity. Informed consent was obtained from all subjects, and the study protocol was approved by the local Helsinki committee. The subjects were assigned to three treatment groups, matched for salivary flow rate and body surface area, and were treated as follows:
1. Two transdermal hyoscine patches (Scopoderm TTSO), and tablets of pyridostigmine-bromide (the S2P1 group, n = 16).
2. Two transdermal hyoscine patches, and placebo tablets (the S2PO group, n = 15). 3. Two placebo patches, and placebo tablets (the SOPO group, n = 16). Each subject was treated with two patches, applied bilaterally to a clean and healthy area of the postauricular skin, for 48 h. Tablets were taken every 8 h. Aiming at steady-state blood concentrations of both drugs during measurements, pyridostigmine and transdermal hyoscine treatments were initiated 27 and 14 h, respectively, before the first measurement of salivation.
Measurement of salivary flow
Salivation was measured by determination (by analytical scales) of the increment of weight of two dental cotton-wool rolls (waterolls) after 6 min in the patient's mouth (under the tongue, one at each side of the frenulum). This method was chosen for its being quick, accurate with relatively minor subjective influence on the results.
Several training sessions were held to acquaint the subjects with the measurement technique. Salivation was measured twice a day (morning and afternoon), four times before drug therapy (baseline), at 14, 21.5, 38 and 45.5 h of transdermal hyoscine therapy, and 14 h after the removal of the patches (Table 1) .
Measurements were performed by the same examiners, at constant hours, 3.75 h after the ingestion of a standard meal, 1 h after drinking 500 ml water. Daily schedule and physical activity were kept constant for all subjects during the study. No smoking was allowed. Air temperature and humidity were continuously monitored, and no significant inter-day variations were observed.
Blood acetylcholinesrease (AChE) activity Whole -blood AChE activity was measured by the radiometric method described by Johnson & Russel (1975) . Blood samples were obtained by venipuncture, and stored in heparin at -20 'C. Analysis was performed within 3 h. According to our previous experience, no significant in vitro decarbamylation is expected under these conditions. Intra-day and interday variabilities of the assay were 3.5% and 6.5%, respectively. AChE activity was measured before drug therapy (baseline), and three times during therapy, 2.5 h after the morning pyridostigmine dose (Table 1) . 
Results
Blood AChE activity
Baseline AChE activity was 6.0 ± 0.85 units (mean + s.d. 1 unit of activity = decomposition of 1 pLmol of acetylcholine in 1 ml whole blood in 1 min). The group treated with pyridostigmine (S2P1) showed an average 23% inhibition of blood AChE activity during drug therapy, which was not observed in the groups treated with placebo tablets (P < 0.001, Figure 1 ). There was no difference in enzymatic activity between the first and second days of treatment, confirming steady-state blood levels during the measurements of salivary flow.
A significant (P < 0.05) 7% average AChE inhibition was still observed in the S2P1 group, 18.5 h after the last pyridostigmine dose.
Salivation (Figure 2)
Baseline salivary flow rate was 0.633 g min-' (mean ± s.d.) The group treated with two transdermal hyoscine patches (S2PO) showed an average reduction of 48% in salivation during the 48 h of drug therapy, significantly (P < 0.01) different from the 24% and 13% reduction observed in the S2P1 and SOPO groups, respectively. The hyposalivation in the S2Po subjects was observed from the first sessions (14 h after application of the patches), and was maintained throughout therapy, with a tendency to be more accentuated in the morning (43% vs 27% in the afternoon).
Salivation in the subjects treated with transdermal hyoscine + pyridostigmine (S2P1) did not significantly differ from that of the placebo-treated group (SOPO). No drug effect on salivation was detected 14 h after the removal of the transdermal patches (19 h after the last pyridostigmine dose).
Discussion
Severe conditions of movement, especially rapid changes in angular and linear acceleration, will induce motion sickness in almost any subject. As estimated by Wood (1979) , two thirds of the population share a moderate to high tendency to develop this syndrome. These facts, along with the proved efficacy of transdermal hyoscine in motion sickness, call for measures that will increase the tolerability of the transdermal formulation.
The present study suggests, that adjunctive treatment with low dosage of pyridostigmine is beneficial in preventing the peripheral side-effects of transdermal hyoscine. Its main finding is that combined treatment of the transcutaneous formulation with 30 mg three times daily of pyridostigmine is not associated with the substantial decrease in salivary excretion, that is otherwise encountered during therapy with the hyoscine patches. This finding is emphasized by the fact, that a dose of two transdermal patches (twice the usual recommended dose) was tested.
The pyridostimine-induced blood AChE inhibition observed in the study was about 23%, values that are in accordance with previous reports, that also confirm, that at these drug dosage and enzymatic inhibition levels no significant side-effects should be expected in healthy subjects (Borland, 1985; Gall, 1981; Graham et al., 1984; Glikson et al., 1991) .
The assumption that pyridostigmine will not impair the efficacy of hyoschine is based on the generally accepted concept, that the evolvement of motion sickness is mediated through neural pathways within the central nervous system (CNS), where integration of sensory information about the motion of the body in space takes place. Motion sickness occurs when these pathways face overwhelming and conflicting sensory input through the visual, vestibular and kinaesthetic sources (Daunton, 1983; Watt et al., 1983) . Several .2o E -30- lines of evidence support this concept (which, however, has to be further tested): 1. There is a direct correlation between the antimotion-sickness activity of drugs and their CNS action (Stott et al., 1989) . 2. It has been shown, that the symptom-complex of motion sickness can be produced by physostigmine, a centrally acting cholinesterase inhibitor. However, this could not be achieved by peripheral AChE inhibitor (neostigmine) (Davis & Davis, 1980; Janowsky, 1984) . Thus, pyridostigmine is not expected to interfere with the CNS mediated, anti-motion sickness activity of hyoscine.
In conclusion, this study presents pyridostigmine as a new and effective tool for the physician who strives to construct the optimal motion sickness prophylactic regimen for the individual patient. Low and adverseeffect-free dosage of the drug can suppress the peripheral anti-cholinergic effects of transdermal hyoscine and increase the convenience of therapy. In some patients, in whom these side effects predominate, this drug combination might even allow some increment in the transdermal hyoscine dose, a measure that has been proved (Pyykko et al., 1985; Larsen & Peitersen, 1983) to increase its anti-motion-sickness activity.
